Objective: The most important genetic factors known in the pathogenesis of Behçet's disease (BD) is HLA-B51. It has been shown that HLA-B51 positivity is high in countries on the 'Silk Road' where BD is frequent. HLA-B51 is thought to be a prognostic marker that is related to severe clinical forms of BD. In this study, we aimed to investigate the prevalence of HLA-B51 positivity in patients diagnosed with BD and the relationship between the demographic and clinical findings of the patients. Material and Methods: Between March 2013 and 2018, the files of the patients who were diagnosed with BD according to the criteria of the International Study Group for Behçet Disease in dermatology polyclinic of Selçuk University Medical Faculty were reviewed retrospectively. Forty-seven patients (22 women and 25 men) with HLA-B51 were included in the study. Results: In our study, no correlation was found between HLA-B51 positivity and gender, age at onset, family history, clinical findings (such as oral and genital ulcer, papulopustular eruption, erythema nodosum, pathergy test positivity, thrombophlebitis, ocular involvement, arthritis) and systemic manifestations. Conclusion: In previous studies, conflicting results have been reported on the relationship between HLA-B51 and BD manifestations in different ethnic groups. In our study, no statistically significant correlation was found between HLA-B51 positivity and demographic and clinical findings of Behçet patients. We believe that there is a need for larger comparative prospective studies investigating the relationship between HLA-B51 and BD in different ethnic groups.
Keywords: Behçet's disease; HLA-B51
Amaç: Behçet hastalığının (BH) patogenezindeki bilinen genetik faktörlerin en önemlisi HLA-B51'dir. Behçet hastalığının sık görüldüğü 'İpek yolu' üzerindeki ülkelerde HLA-B51 pozitifliğinin yüksek olduğu gösterilmiştir. HLAB-51'in, BH'nin şiddetli klinik formları ile ilişkili prognostik bir marker olabileceği düşünülmüştür. Bu çalışmada, BH tanısı ile takip edilen hastalarda, HLA-B51 pozitifliğinin sıklığı ve hastaların demografik ve klinik bulguları ile ilişkisini araştırmayı amaçladık. Gereç ve Yöntemler: Mart 2013-2018 tarihleri arasında Selçuk Üniversitesi Tıp Fakültesi dermatoloji polikliniğinde takip edilen, Uluslararası Behçet Hastalığı Çalışma Grubu kriterlerinine göre BH tanısı olan hastaların dosyaları retrospektif olarak incelendi. HLA-B51 bakılan 47 hasta (22 kadın ve 25 erkek) çalışmaya dahil edildi. Bulgular: Çalışmamızda HLA-B51 pozitifliği ile cinsiyet, başlangıç yaşı, aile öyküsü, klinik bulgular (oral ve genital ülser, papülopüstüler erüpsiyon, eritema nodozum, paterji testi pozitifliği, tromboflebit, oküler tutulum, artrit gibi) ve sistemik bulgular arasında bir ilişki bulunmadı. Sonuç: Daha önceki çalışmalarda, farklı etnik gruplarda, HLA-B51'in BH'nin klinik bulguları arasındaki ilişkiyle ilgili çelişkili sonuçlar bildirilmiştir. Bizim çalışmamızda HLA-B51 pozitifliği ile Behçet hastalarının demografik ve klinik özellikleri arasında istatistiksel olarak anlamlı bir ilişki bulunamamıştır. Bu nedenle HLA-B51 ile BH'nin ilişkisini araştıran farklı etnik grupları kapsayan daha geniş karşılaştırmalı prospektif çalışmalara ihtiyaç vardır.
Anahtar Kelimeler: Behçet hastalığı; HLA-B51
- Sakane T, Takeno M, Suzuki N, Inaba G. Behcet's disease. N Eng J Med. 1999;341(17):1284-91. [Crossref] [PubMed]
- Tursen U, Gurler A. [Behcet's disease and genetics]. Turkiye Klinikleri J Dermatol. 2000;10(1):37-43.
- Alpsoy E. [Behcet's disease: epidemiology]. Turkiye Klinikleri J Dermatol-Special Topics. 2017;10(4):265-70.
- Acar A, Turk BG. [Etiology and pathogenesis]. Turkiye Klinikleri J Dermatol-Special Topics. 2017;10(4):271-7.
- Maldini C, Lavalley MP, Cheminant M, de Menthon M, Mahr A. Relationships of HLA-B51 or B5 genotype with Behcet's disease clinical characteristics: systematic review and meta-analyses of observational studies. Rheumatology (Oxford). 2012;51(5):887-900. [Crossref] [PubMed]
- Hamzaoui A, Houman MH, Massouadia M, Ben Salem T, Khanfir MS, Ben Ghorbel I, et al. Contribution of Hla-B51 in the susceptibility and specific clinical features of Behcet's disease in Tunisian patients. Eur J Intern Med. 2012;23(4):347-9. [Crossref] [PubMed]
- Demirseren DD, Ceylan GG, Akoglu G, Emre S, Erten S, Arman A, et al. HLA-B51 subtypes in Turkish patients with Behcet's disease and their correlation with clinical manifestations. Genet Mol Res. 2014;13(3):4788-96. [Crossref] [PubMed]
- Cicek D, Demir B, Koca SS, Coban FG. [Disease activity scores and laboratory]. Turkiye Klinikleri J Dermatol-Special Topics. 2017;10(4):321-9.
- Ohno S, Ohguchi M, Hirose S, Matsuda H, Wakisaka A, Aizawa M. Close association of HLA-Bw51 with Behcet's disease. Arch Ophthalmol. 1982;100(9):1455-8. [Crossref] [PubMed]
- Ohno S, Asanuma T, Sugiura S, Wakisaka A, Aizawa M, Itakura K. HLA-Bw51 and Behcet's disease. JAMA. 1978;240(6):529. [Crossref] [PubMed]
- Gul A. Genetics of Behcet's disease: lessons learned from genomewide association studies. Curr Opin Rheumatol. 2014;26(1):56-63. [Crossref] [PubMed]
- Giza M, Koftori D, Chen L, Bowness P. Is Behcet's disease a 'class 1-opathy'? The role of HLA-B*51 in the pathogenesis of Behcet's disease. Clin Exp Immunol. 2018;191(1):11-8. [Crossref] [PubMed] [PMC]
- Dalvi SR, Yildirim R, Yazici Y. Behcet's syndrome. Drugs. 2012;72(17):2223-41. [Crossref] [PubMed]
- Zouboulis CC. Epidemiology of adamantiades-Behcet's disease. Ann Med Interne (Paris). 1999;150(6):488-98.
- Direskeneli H, Eksioglu-Demiralp E, Kibaroglu A, Yavuz S, Ergun T, Akoglu T. Oligoclonal T cell expansions in patients with Behcet's disease. Clin Exp Immunol. 1999;117(1):166-70. [Crossref] [PubMed] [PMC]
- Kaya TI, Dur H, Tursen U, Gurler A. Association of class I HLA antigens with the clinical manifestations of Turkish patients with Behcet's disease. Clin Exp Dermatol. 2002;27(6):498-501. [Crossref] [PubMed]
- Kirino Y, Nakajima H. Clinical and genetic aspects of Behcet's disease in Japan. Intern Med. 2019;58(9):1199-207. [Crossref] [PubMed] [PMC]
- Koumantaki Y, Stavropoulos C, Spyropoulou M, Messini H, Papademetropoulos M, Giziaki E, et al. HLA-B*5101 in Greek patients with Behcet's disease. Hum Immunol. 1998;59(4):250-5. [Crossref]
- Chang HK, Kim JU, Cheon KS, Chung HR, Lee KW, Lee IH. HLA-B51 and its allelic types in association with Behcet's disease and recurrent aphthous stomatitis in Korea. Clin Exp Rheumatol. 2001;19(5 Suppl 24):S31-5.
- Ryu HJ, Seo MR, Choi HJ, Baek HJ. Clinical phenotypes of Korean patients with Behcet disease according to gender, age at onset, and HLA-B51. Korean J Intern Med. 2018;33(5):1025-31. [Crossref] [PubMed] [PMC]
- Soylu M, ?ekero?lu HT, Erdem E, Demircan N. Behcet's disease: the clinical and demographic characteristics of 406 patients. J Rheumatol. 2012;27(2):115-20. [Crossref]
- Tuna S, Alan S, Turkoglu EB. Effects of smoking and HLA-B51 on clinical manifestations in Behcet's disease: retrospective analysis of 209 patients in a Turkish population. Arch Rheumatol. 2015;30(4):319-25. [Crossref]
- Calamia KT, Wilson FC, Icen M, Crowson CS, Gabriel SE, Kremers HM. Epidemiology and clinical characteristics of Behcet's disease in the US: a population-based study. Arthritis Rheum. 2009;61(5):600-4. [Crossref] [PubMed] [PMC]
- Muftuoglu AU, Yazici H, Yurdakul S, Pazarli H, Ozyazgan Y, Tuzun Y, et al. Behcet's disease: lack of correlation of clinical manifestations with HLA antigens. Tissue Antigens. 1981;17(2):226-30. [Crossref] [PubMed]
- Tursen U, Gurler A, Boyvat A. Evaluation of clinical findings according to sex in 2313 Turkish patients with Behcet's disease. Int J Dermatol. 2003;42(5):346-51. [Crossref] [PubMed]
.: Process List